Brant Point Investment Management LLC Increases Holdings in Thermo Fisher Scientific Inc. $TMO

Brant Point Investment Management LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.8% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 17,829 shares of the medical research company’s stock after acquiring an additional 1,132 shares during the quarter. Thermo Fisher Scientific comprises 0.8% of Brant Point Investment Management LLC’s investment portfolio, making the stock its 13th biggest holding. Brant Point Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $7,229,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in Thermo Fisher Scientific by 0.9% during the second quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock worth $13,700,154,000 after purchasing an additional 309,207 shares in the last quarter. Norges Bank acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $2,264,615,000. Franklin Resources Inc. lifted its position in Thermo Fisher Scientific by 11.3% in the second quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock valued at $1,985,759,000 after acquiring an additional 498,238 shares during the last quarter. Amundi boosted its stake in Thermo Fisher Scientific by 5.9% in the first quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock valued at $1,426,316,000 after acquiring an additional 168,197 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 2.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock worth $1,216,612,000 after purchasing an additional 74,971 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Michel Lagarde sold 22,046 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the sale, the chief operating officer owned 84,117 shares of the company’s stock, valued at approximately $47,404,976.52. The trade was a 20.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 7,250 shares of the stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $64,400,668.20. This trade represents a 5.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 149,271 shares of company stock valued at $86,507,282 in the last quarter. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Barclays raised their target price on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Evercore ISI lifted their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Finally, Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $609.38.

Thermo Fisher Scientific Stock Down 0.5%

Shares of NYSE:TMO opened at $572.49 on Monday. The company has a market cap of $215.09 billion, a price-to-earnings ratio of 33.07, a PEG ratio of 4.19 and a beta of 0.90. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The firm’s 50-day simple moving average is $559.70 and its 200-day simple moving average is $486.12. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter last year, the firm earned $5.28 earnings per share. The firm’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has authorized a share repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.